• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota

    2021-11-11 13:37:54ZhengWeiZhangLinCongRanPengPeiHanShuRongMaLiBinPanJieFuHangYuYanWangJianDongJiang
    Journal of Pharmaceutical Analysis 2021年5期

    Zheng-Wei Zhang , Lin Cong , Ran Peng, Pei Han, Shu-Rong Ma, Li-Bin Pan, Jie Fu,Hang Yu, Yan Wang, Jian-Dong Jiang

    State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking Union Medical College, Beijing,100050, China

    Keywords:Berberine Biotransformation Gut microbiota CYP51 Demethylated metabolite

    ABSTRACT Berberine (BBR) is an isoquinoline alkaloid extracted from Coptis chinensis that improves diabetes,hyperlipidemia and inflammation. Due to the low oral bioavailability of BBR, its mechanism of action is closely related to the gut microbiota. This study focused on the CYP51 enzyme of intestinal bacteria to elucidate a new mechanism of BBR transformation by demethylation in the gut microbiota through multiple analytical techniques. First, the docking of BBR and CYP51 was performed; then, the pharmacokinetics of BBR was determined in ICR mice in vivo,and the metabolism of BBR in the liver,kidney,gut microbiota and single bacterial strains was examined in vitro.Moreover,16S rRNA analysis of ICR mouse feces indicated the relationship between BBR and the gut microbiota. Finally, recombinant E. coli containing cyp51 gene was constructed and the CYP51 enzyme lysate was induced to express.The metabolic characteristics of BBR were analyzed in the CYP51 enzyme lysate system.The results showed that CYP51 in the gut microbiota could bind stably with BBR,and the addition of voriconazole(a specific inhibitor of CYP51) slowed down the metabolism of BBR, which prevented the production of the demethylated metabolites thalifendine and berberrubine. This study demonstrated that CYP51 promoted the demethylation of BBR and enhanced its intestinal absorption, providing a new method for studying the metabolic transformation mechanism of isoquinoline alkaloids in vivo.

    1. Introduction

    The human intestine is the natural host of many microorganisms [1], and the gut microbiota is a complex group containing hundreds of times more genes than the human genome [2].Referred to as a“hidden organ”of the body[3],the gut microbiota has been reported to be associated with many diseases, including obesity [4], functional bowel disease, colitis [5-8] and cardiovascular disease [9]. There are many metabolic enzymes in the gut microbiota,such as β-glucuronidase,β-glucosidase, nitroreductase and azoreductase [10,11]. These enzymes can interact with oral drugs and produce metabolites that are different from those produced by organs [12]. Therefore, the gut microbiota has good biotransformation ability and can participate in the metabolism of oral natural products in vivo. In addition, studies have shown that regulation of the composition of gut microbiota can contribute to disease treatment [13-15].

    Sterol 14α-demethylase (P45014DM, CYP51) is a key biosynthetic enzyme [16] belonging to the cytochrome P450 family of enzymes, which catalyze the 14α-methyl hydroxylation of sterol precursors [17,18]. More than 100 CYP51 sequences have been found in 82 species, some of which contain multiplecyp51genes.Meanwhile, as the P450 enzyme in bacteria, fungi, lower eukaryotes,higher plants and mammals,CYP51 catalyzes the metabolism of xenobiotics through demethylation.It has been found that CYP51 has five kinds of substrates, including lanosterol, 24,25-dihydrolanosterol, 24-methylene-24,25-dihydrolanosterol, obtusifoliol, and 4β-desmethyllanosterol [19]. These substrates can be demethylated by CYP51. For example, lanosterol can be metabolized by CYP51 to 14-demethyl-14-dehydrolanosterol (FF-MAS). In addition, studies have shown that one of the main metabolic pathways of isoquinoline alkaloids is demethylation,which may be closely related to CYP51, as shown by docking simulation [20].

    Berberine(BBR),a quaternary ammonium alkaloid isolated from the traditional Chinese medicine Coptis chinensis,is present in six plant families (Oleaceae, Papaveraceae, Ranunculaceae, Rutaceae,Menispermaceae, and Rhamnaceae) that were originally used as antipyretic,antidote and antibacterial drugs in clinical practice[21].In recent years,studies have shown BBR to be a new lipid-lowering drug, acting by lowering cholesterol, triglyceride and low-density lipoprotein levels, which is different from the mechanism of action of statins[22].Studies have demonstrated that rats exhibit 16 metabolites in their bile,urine and feces after oral administration of BBR [23] (Fig.1A), most of which are related to the demethylation process.

    Therefore,the main metabolic process of BBR in vivo called the demethylation reaction was studied.This study would demonstrate that CYP51 promotes the demethylation of BBR and provides a new method for studying the metabolic transformation mechanism of isoquinoline alkaloids in vivo.

    2. Experimental

    2.1. Materials and reagents

    BBR was obtained from J&K Scientific Ltd. (Beijing, China).Rotundine (internal standard-1, IS-1) was purchased from the Institute for Food and Drug Control (Beijing, China). Benzylamine(IS-2) was purchased from J&K Scientific, Ltd. (Beijing, China).Thalifendine (M1) was purchased from Shanghai Hekang Biotechnology Co., Ltd. (Shanghai, China). Berberrubine (M2) was purchased from Chengdu Herbipurify Co., Ltd. (Chengdu, China).Voriconazole was purchased from Beijing Solarbio Science &Technology Co., Ltd. (Beijing, China). Lanosterol was purchased from Chengdu Pufei De Biotech Co., Ltd. (Chengdu, China).Enterobacter cloacae,Enterococcus faecium,Staphylococcus epidermidis,Enterococcus faecalis,Pseudomonas aeruginosa,Acinetobacterbaumannii,Staphylococcus aureus,Escherichia coli,Klebsiella pneumoniae,Proteus mirabilis,Bifidobacterium longum,Bifidobacterium breve,Lactobacillus acidophilus, andLactobacillus caseiwere purchased from Nanjing Lezhen Biotechnology Co., Ltd. (Nanjing,China). The sterol 14α-demethylase ELISA Kit was purchased from Nanjing Jin Yibai Biological Technology Co., Ltd. (Nanjing, China).

    2.2. Animals

    ICR mice (male,19-21 g) were obtained from SiPeiFu Biotechnology Co.,Ltd.(Beijing,China)with the license No.SCXK(Beijing)2016-0002,and the experimental conditions were as follows:12 h light/dark cycle, 8 a.m. to 8 p.m.; ambient temperature 20-25°C;and relative humidity 40%-70%. All animals were fasted for 12 h before starting the experiment. Animal experiments were approved by the Animal Medicine and Experimental Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College, China in accordance with institutional guidelines and ethical guidelines.

    2.3. Instruments

    The following instruments were used: LC-MS/MS-8050 (Shimadzu Corporation, Kyoto, Japan), LC-MS/MS-8060 (Shimadzu Corporation,Kyoto,Japan)and LC-MS solution workstation for online analysis of metabolites (Shimadzu Corporation, Kyoto, Japan);FSH-2 adjustable high-speed homogenizer (Jitan Shenglan Instrument Manufacturing Co., Ltd., Jitan, China); Heraeus Pico21 microcentrifuge (Thermo Fisher Scientific, Dreieich, Germany);MD200-2 nitrogen-blowing instrument (Hangzhou Diansheng Instrument Co., Ltd., Hangzhou, China); ThermoMixer (Eppendorf,Hamburg, Germany); Spectra Max Model 190 microplate reader(Molecular Devices, Silicon Valley, CA, USA).

    BBR and its metabolites from each sample in vitro/in vivo and enzymatic reaction studies were analyzed by using a Shimpack XR0ODS II column(75 mm×3 mm,2.3 μm,Shimadzu Corporation,Kyoto, Japan) at a column temperature of 40°C. The mobile phase consisted of water-formic acid (0.5%,V/V) and acetonitrile with a gradient elution (0 min, 90:10; 3.5 min, 75:25; 5.0 min, 70:30;5.01 min, 80:20; 6.0 min,90:10); the flow rate was 0.4 mL/min.

    Lanosterol and 14-demethyl-14-dehydrolanosterol (FF-MAS)from each sample in the enzymatic reaction study were analyzed by using Alltima TM C18column (4.6 mm × 150 mm, 5 μm) at a column temperature of 40°C.The mobile phase consisted of waterammonia (0.5%,V/V) and acetonitrile, with a gradient elution(0.01 min, 70:30; 2 min, 95:5; 7.0 min, 95:5; 7.01 min, 70:30;10.0 min, stop); the flow rate was 0.4 mL/min. The ESI+ mode analysis was used, and the specific parameters were as follows:nebulizer gas flow rate, 3.0 L/min; dry gas flow rate, 10.0 L/mL;interface voltage,-4.5 kV;collision-induced dissociation pressure,230 kPa; desolvation line temperature, 250°C; and heating block temperature, 400°C. Multiple reaction monitoring modes were used to quantify the sample. Them/ztransitions werem/z335.70 →320.10 for BBR,m/z355.70 →191.90 for IS-1,m/z321.65 → 307.15 for M1,m/z321.65 → 307.15 for M2,m/z409.15 →353.30 for lanosterol,m/z393.20 →151.10 for FF-MAS,andm/z108.20 →91.10 for IS-2.

    2.4. Method of molecular docking

    The interaction between BBR and CYP51 was simulated using Discovery Studio software (v16.1.0.15350). The crystal structure of CYP51 was obtained from the Protein Database (PDB) with PDB ID 2W09.

    The BBR structure was constructed using ChemDraw15.0, and the structure of the target compound was subjected to energy minimization by the minimization module in Discovery Studio Client software (v16.1.0.15350) to obtain an optimized structure.The CDOCKER method was selected to simulate the interaction between the target compound and the protein after optimization.The pose cluster radius parameter was set to 0.5,and the rest of the parameters were set to default values.

    2.5. Analytical methods of BBR pharmacokinetics in vivo

    Animals were divided into BBR group and voriconazole group,and the ICR mice were given 200 mg/kg BBR and 200 mg/kg BBR +30 mg/kg voriconazole in single oral administrations. After administration for 0.17,0.33,0.5,1,1.5,2,3,4,6,12,and 24 h,blood was taken from the retrobulbar venous plexus and transferred to a sample tube to which heparin had been added. Samples were stored at -20°C prior to analysis. After 3 h of administration, the mice were free to eat. All animal programs were approved by the Animal Care Welfare Committee of the Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China). In addition, all animal experiments were conducted in strict accordance with the Laboratory Animal Care and Use Guidelines issued by the Animal Protection and Welfare Institute.

    The plasma (100 μL) was added to 300 μL of methanol (containing 50 ng/mL IS)to precipitate the protein.After vortexing,the tubes were centrifuged at 10,800 rpm for 10 min, the supernatant was extracted, and 2 μL was injected. The concentrations used for the standard curve were as follows: 1, 2,10,100, and 1000 ng/mL.

    The two-compartment model was used to simulate pharmacokinetic parameters, and the data were analyzed by using DAS 3.0.

    2.6. Preparation of intestinal bacterial incubation in vitro

    An anaerobic medium for intestinal bacteria was prepared according to literature reports [11]. The obtained medium was autoclaved at 0.1 MPa and 121°C for 20 min and used after being cooled.

    Intestinal bacterial cultures were prepared according to literature reports[24].After being anesthetized,the mice were sacrificed by cervical dislocation. The abdomen was incised, the colon was removed, and the colon contents were homogenized in an anaerobic chamber.After mixing 1 g of the contents in 20 mL of anaerobic medium, the cultures were incubated at 37°C for 60 min under anaerobic conditions (N2environment) and set aside.

    The samples were divided into five groups: negative control group; the 10, 50, and 100 mg/mL BBR groups; and the 50 mg/mL BBR + 3.5 μg/mL voriconazole group. BBR and voriconazole were dissolved in methanol;BBR was formulated at concentrations of 10,50, and 100 mg/mL; and voriconazole was formulated at a concentration of 3.5 μg/mL. Then, 10 μL of the sample solution was added to each sample tube,1 mL of the intestinal culture medium was added in an anaerobic chamber, and the sample tubes were sealed with sealing films and incubated at 37°C for 12, 24,36, 48,60,and 72 h while using methanol as a negative control.When the incubation was completed, the samples were removed, added to 1 mL of methanol,vortexed for 30 s and centrifuged at 14,800 rpm for 15 min. The supernatant was diluted in groups as follows: 10 times for the 10 mg/mL BBR group;50 times for the 50 mg/mL BBR group; 100 times for the 100 mg/mL BBR group, and 50 times for the 50 mg/mL BBR+3.5 μg/mL voriconazole group.After dilution,100 μL of each sample was added to 300 μL of methanol(containing 50 ng/mL IS), vortexed and centrifuged at 14,800 rpm for 10 min.The supernatant was extracted, and 2 μL was injected. The concentrations used for the standard curve were as follows: 1, 2, 10,100, and 1000 ng/mL.

    2.7. Preparation of liver and kidney homogenates for BBR metabolism in vitro

    The mice were sacrificed by cervical dislocation, and the abdomen was incised to remove the liver and kidneys.With a ratio of 1 g of organ to 5 mL of physiological saline, the samples were homogenized for use.

    Liver and kidney homogenates were divided into two groups:BBR group (50 mg/mL) and voriconazole (3.5 μg/mL) group. BBR was formulated to a concentration of 50 mg/mL, and voriconazole was formulated to a concentration of 3.5 μg/mL.Then,10 μL of the sample solution was added to each sample tube, and 1 mL of the organ homogenate was added and incubated at 37°C for 0,15,30,60, 90, and 120 min. When the incubation was completed, the samples were removed, treated with 1 mL of methanol, vortexed for 30 s and centrifuged at 14,800 rpm for 15 min.Then,100 μL of the supernatant of each sample was added to 300 μL of methanol(containing 50 ng/mL IS).Subsequently,the samples were vortexed and centrifuged at 14,800 rpm for 10 min. The supernatant was extracted, and 2 μL was injected. The concentrations used for the standard curve were as follows: 1, 2,10,100, and 1000 ng/mL.

    2.8. Preparation of liver and kidney microsomal for BBR metabolism in vitro

    The mice were sacrificed by cervical dislocation, and the liver and kidneys were removed into beakers containing physiological saline at 4°C. Then, the organs were washed until no blood remained; filter paper was used to blot the remaining liquid; the excess tissues were removed and weighed; Tris-KCl was added at 2 mL/g according to the weight of the organ so that the mixture was homogenized. Then, the homogenate was centrifuged at 10,000gand 4°C for 25 min to extract the supernatant.After the addition of Tris solution,sample centrifugation was continued at 105,000gand 4°C for 1 h. Then, the supernatant was discarded, and the precipitate was resuspended with an appropriate amount of Tris-KCl and centrifuged at 105,000gand 4°C for 1 h. Finally, the supernatant was discarded again, 8 mL of Tris-KCl was added and the sample was suspended to obtain the prepared liver and kidney microsomes.

    Liver and kidney microsomes were divided into two groups:BBR group (50 mg/mL) and voriconazole group (50 mg/mL BBR + 3.5 μg/mL voriconazole). BBR was formulated to a concentration of 50 mg/mL, voriconazole was formulated to a concentration of 3.5 μg/mL and the NADPH generation system was formulated as follows:1.3 mmol/L NADP,3.3 mmol/L G-6-P,0.4 U/mL G-6-PD,and 3.3 mmol/L MgCl2.The prepared mouse liver and kidney microsomes were diluted with 4°C Tris buffer (pH 7.4)until the protein concentration was 0.5 mg/mL. After incubation for 3 min at 37°C in advance,10 μL of sample solution and NADPH solution were added and incubated at 37°C for 0,15, 30, 60, 90,and 120 min.Then,100 μL of the supernatant of each sample was added to 300 μL of methanol (containing 50 ng/mL IS). Subsequently,the samples were vortexed and centrifuged at 14,800 rpm for 10 min.The supernatant was extracted,and 2 μL was injected.The concentration of the standard curve was as follows: 1, 2,10,100, and 1000 ng/mL.

    2.9. Preparation of standard bacterial strains for BBR metabolism in vitro

    The number of colonies of 14 standard bacterial strains on culture medium was counted by the plate method after resuscitating the cells.According to the results after counting,the culture media for the standard bacterial strains were diluted until the bacterial concentrations were the same.

    Then, 0.9 mL of sterilized anaerobic medium and 100 μL of the diluted 14 standard bacterial cultures were added to each sample tube in an anaerobic chamber. Then, each tube was blown with nitrogen and sealed. After incubation at 37°C for 1 h in advance,10 μL of BBR(50 mg/mL)was added to each sample,which was then incubated at 37°C for 24 h. Then, 1 mL of methanol (containing 50 ng/mL IS) was added to each sample, which was then vortexed and centrifuged at 14,800 rpm for 10 min. The supernatant was extracted, and 2 μL was injected. The concentrations used for the curve were as follows: 1, 2,10,100, 500, and 1000 ng/mL.

    Samples of each standard bacterial strain were divided into three groups after four single strains were screened: negative control group (methanol), BBR group (50 mg/mL BBR), and voriconazole group (50 mg/mL BBR + 3.5 μg/mL voriconazole). The four standard bacterial strains, namely,E. faecalis,S. epidermidis,E. cloacae, andE. faecium, were mixed with 50 mg/mL BBR and incubated to determine the concentration of BBR and the activity of CYP51 at 48 and 72 h.Then,the percentage of BBR metabolism was calculated.

    The 0.9 mL of sterilized anaerobic culture medium and 100 μL of the diluted single-culture medium were added to each sample in an anaerobic chamber. Then, each tube was blown with nitrogen,sealed, incubated at 37°C for 24 h and ultrasonically disrupted.Then,the activity of CYP51 was determined by the CYP51 ELISA Kit.

    2.10. 16S rRNA analysis of ICR mouse feces

    By using 16S V3-V4:340-805R specific primers, the V3-V4 region of 16S rRNA was targeted, and the 16S rRNA gene was amplified. The PCR products were mixed in equal proportions.Then,the PCR products were purified by the OMEGA Gel Extraction Kit. The sequencing library was constructed using the NEXTflex Rapid Illumina DNA-seq Kit, while the quality of the library was tested by using a Qube 2 fluorometer and an Agilent Bioanalyzer 2100. Finally, the library was sequenced on the HISEQ 2500 platform, and 250-bp paired-end reads were generated.

    Sequences were analyzed using Quantitative Insights Into Microbial Ecology(QIIME)software.First,the reads were classified by using the quality filters module of QIIME. Then, each operational taxonomic unit (OTU) was selected for a representative sequence,and the classification information for each representative sequence was annotated by using the Ribosomal Database Project classifier.Sequences with similarity >97% were assigned to the same OTU.

    2.11. Expression and functional verification of CYP51

    Thecyp51gene ofSaccharomyces cerevisiaeS288C(NC_022591.1) was synthesized by Sangon Biotech (Shanghai,China).Thecyp51gene was amplified using primer-F/primer-R.The primers for thecyp51gene were designed by Primer 5.0 as follows:cyp51-F: AGCAAATGGGTCGCGGATCCAGCGCGACCAAAAGCATCG;cyp51-R: TCGAGTGCGGCCGCAAGCTTGATTTTCTGTTCCGGGTTACGT.Thirty-five cycles of PCR were performed with Phanta polymerase(Vazyme Biotech Co.,Ltd.,Nanjing,China)in a 50-μL system.Then,1% agarose gel electrophoresis and gene sequencing were performed to verify the gene amplification. Thecyp51fragment was cloned between the HindIII/BamHI sites of the expression vector pET28a (New England Biolabs, Ipswich, MA, USA) using Gibson Assembly Master Mix(New England Biolabs,Ipswich,MA,USA)to obtain pET28a-cyp51.

    The plasmid pET28a-cyp51was introduced intoE.coliBL21 cells(Vazyme Biotech Co., Ltd., Nanjing, China). After verifying the sequence, clones were used to express the cyp51 protein(ONH80457.1).E.coliBL21 colonies with pET28a-cyp51were grownin 100 mL of Luria-Bertani broth containing 15 μg/mL kanamycin at 37°C. When the amplified bacterial solution reached an OD600of 0.6-0.8,isopropyl β-D-1-thiogalactopyranoside was added at a final concentration of 0.1 mM to induce expression, and the cells were grown at 16°C for 20 h.After centrifugation,the bacterial cells were suspended in 10 mL of phosphate buffered saline (PBS) solution,andE.coliBL21 with a pet28a plasmid lacking theCYP51gene was used as a control. Supernatants and pellets were prepared for SDS gel electrophoresis. After concentrating to 1 mL through a microporous membrane(MWCO:30,000),the concentrated solution was used for functional verification.

    The enzymatic reaction system was composed of PBS solution(1×) containing NADPH (0.5 mM), enzyme lysate(10 μL), and lanosterol(10 μg/mL),and incubated for 0,1,2,and 4 h.The products obtained after incubation were used to analyze lanosterol and FFMAS by LC-MS/MS. The enzymatic reaction system was composed of 1×PBS solution containing NADPH (0.5 mM), enzyme lysate(10 μL),and substrate BBR(10 μg/mL),and incubated for 0,1,2,and 4 h. The products obtained after incubation were used to analyze M1 and M2 by LC-MS/MS.

    2.12. Statistical analysis

    Statistical analysis was performed using ANOVA and Student'sttest in GraphPad Prism version 5 (GraphPad, San Diego, CA, USA).The data are expressed as mean ± standard deviation (SD), andPvalues less than 0.05 are considered statistically significant.

    3. Results and discussion

    3.1. Molecular docking between BBR and CYP51

    The putative chemical mechanism for the docking of BBR alkaloids by CYP51 (PDB ID: 2W09) is shown in Fig.1B. Based on the results of molecular docking, BBR can stably bind to CYP51 with a binding energy of-23.1 kcal/mol(Fig.1C).In addition,the form of action demonstrated that the BBR structure can form various bonds with CYP51 for tight binding to promote the demethylation effect of CYP51 (ring b of BBR formed π bonds with the alkyl group of Met79; ring d of BBR formed π bonds with the alkyl group of Ala256;ring e of BBR simultaneously formed π bonds with the alkyl group of Ala256 and the sulfhydryl group of Cys394;the oxygen in the 10th methoxy group of BBR formed hydrogen bonds with Val395).

    3.2. Pharmacokinetics of BBR in vivo

    According to the above results,it could be inferred that BBR was likely to produce demethylated metabolites by CYP51-mediated metabolism. Therefore, a BBR metabolism experiment was conducted in ICR mice,and the BBR metabolic mechanism in vivo was explored.As shown in Table 1,the AUC(0-24h)increased by 9.8%,t1/2increased by 17.4%, andCmaxincreased by 45.7% after addition of voriconazole (Fig. 1E) compared with the values after oral administration of 200 mg/kg BRR alone (Fig.1D). Moreover, there were double peaks in the drug-time curve. It was speculated that this might be attributed to enterohepatic circulation after oral administration.

    Table 1 The pharmacokinetic parameters of ICR mice after oral administration of berberine(BBR) simulated by a two-compartment model.

    Fig.2.Metabolism of BBR by the mice gut microbiota in vitro.(A)Percentage of residual BBR(10,50,and 100 mg/mL)after intestinal metabolism in mice in vitro.(B)Level of M1 produced from BBR(10,50,and 100 mg/mL)after intestinal metabolism in mice in vitro.(C)Level of M2 produced from BBR(10,50,and 100 mg/mL)after intestinal metabolism in mice in vitro.(D)Comparison of the percentage of residual BBR(50 mg/mL) metabolized in the gut microbiota under the influence of an inhibitor(voriconazole,3.5 μg/mL). *P <0.05;**P <0.01.(E)Comparison of the M1 content produced by BBR(50 mg/mL)metabolism in the gut microbiota under the influence of an inhibitor(voriconazole,3.5 μg/mL).**P <0.01;***P <0.001.(F)Comparison of the M2 content produced by BBR(50 mg/mL)metabolism in the gut microbiota under the influence of an inhibitor(voriconazole,3.5 μg/mL). * P <0.05; ** P <0.01.

    Fig.3.Metabolism of BBR in the liver and kidney system in vitro.(A and B)Comparison of M1 and M2 levels produced by BBR(50 mg/mL)metabolism in liver homogenate under the influence of an inhibitor (voriconazole, 3.5 μg/mL). (C and D) Comparison of M1 and M2 levels produced by BBR (50 mg/mL) metabolism in kidney microsomes under the influence of an inhibitor(voriconazole,3.5 μg/mL).(E and F)Comparison of M1 and M2 levels produced by BBR(50 mg/mL)metabolism in kidney homogenate under the influence of an inhibitor (voriconazole, 3.5 μg/mL). (G and H) Comparison of M1 and M2 levels produced by BBR (50 mg/mL) metabolism in kidney microsomes under the influence of an inhibitor (voriconazole, 3.5 μg/mL).

    Thus, it could be inferred that voriconazole reduced the metabolic capacity of BBR by inhibiting the enzyme activity and slowing the BBR metabolic process,which finally increased thet1/2,AUC andCmaxof BBR in mouse plasma.

    3.3. Pharmacokinetics of M1 and M2 in vivo

    The production of M1 was more than that of M2 in mice after oral administration of BBR.In addition,the M1 and M2 levels were all below the lower limit of quantitation(1 ng/mL)and could not be detected at any of the time points under the influence of voriconazole (Figs. 1F and G), which indirectly proved that voriconazole had entered the gut microbiota.It indicated that after oral administration of voriconazole, BBR could not be converted to M1 or M2 by the demethylation pathway in vivo.Therefore,combined with the results of pharmacokinetic studies, this result indicated that the demethylation process of BBR in vivo was mediated by CYP51.

    Fig.4.Metabolism of BBR in standard bacterial strains in vitro.(A)Comparison of M1 content produced by BBR metabolism in 14 standard bacterial strains.*P <0.05;**P <0.01.(B and C) Percentage of BBR metabolized by 4 standard bacterial strains after 48 h and 72 h. * P <0.05; ** P <0.01. (D and E) Activity of CYP51 in 4 standard bacterial strains after metabolism of BBR for 48 h and 72 h. * P <0.05; ** P <0.01; *** P <0.001. (F and G) Comparison of M1 and M2 levels produced by BBR (50 mg/mL) metabolism in 4 standard bacterial strains for 72 h under the influence of an inhibitor (voriconazole, 3.5 μg/mL). * P <0.05; ** P <0.01; ND: not detected. (H) Comparison of CYP51 activity in 4 standard bacterial strains after metabolism of BBR (50 mg/mL) for 72 h under the influence of an inhibitor (voriconazole, 3.5 μg/mL) ** P <0.01; *** P <0.001.

    3.4. Metabolism of BBR by the mice gut microbiota in vitro

    Different concentrations of BBR (10, 50, and 100 mg/mL) and mouse colon contents were mixed and incubated for 72 h,and the contents of BBR, M1 and M2 were determined. After 12 h of incubation, the production of M1 was 15, 47, and 76 μg/mL while the production of M2 was 44, 98, and 131 μg/mL, respectively. After 72 h of incubation,the production of M1 was 47,100,and 113 μg/mL while the production of M2 was 93,292,and 337 μg/mL.From the above results,it could be known that the production of M2(Fig.2C)was nearly 3 times (the range was 1.73-2.98) higher that of M1(Fig. 2B) when BBR was metabolized by gut microbiota in vitro.After 72 h of incubation,BBR could not be completely metabolized(Fig. 2A). At the same time, the percentage of BBR metabolized at each concentration was different, and the percentage of BBR metabolized at 10, 50, and 100 mg/mL concentrations decreased sequentially. It was speculated that the concentration of intestinal bacteria and the activity of CYP51 in each system were constant,so the metabolic capacity of BBR was certain,which further resulted in the difference in the percentage of BBR metabolism at each concentration. In addition, BBR could be metabolized in the mouse intestinal microsomes and M1 and M2 were produced. However,the production of M1 and M2 was very low (Figs. S1A and B). The production of M1 was decreased by 21%,25%,and 20%at 30,60,and 120 min after adding voriconazole(Fig.S1A)and the production of M2 was decreased by 28%, 26%, and 30% at 30, 60, and 120 min,respectively(Fig.S1B).This showed that the demethylation of BBR in the intestine was mainly mediated by gut microbiota and CYP51 played a key role in the metabolism of BBR.

    However, the percentage of residual BBR was significantly increased (Fig. 2D) after the addition of voriconazole (3.5 μg/mL).Furthermore, the production of M1 (Fig. 2E) and M2 (Fig. 2F) was significantly decreased sequentially compared with that in the BBR group. This further demonstrated that voriconazole could specifically inhibit the activity of CYP51, thereby reducing the ability of intestinal bacteria to metabolize BBR and produce M1 and M2.

    3.5. Metabolism of BBR in the liver and kidney system in vitro

    The mouse liver homogenates and liver microsomes were mixed and incubated with BBR(50 mg/mL)and voriconazole(3.5 μg/mL),respectively. Then, the levels of M1 and M2 in the mixture were determined at different time points. After the addition of voriconazole (3.5 μg/mL), BBR could still be metabolized in the liver homogenate, and M1 and M2 were produced, but the production was partially reduced (Figs. 3A and B). Similar results were also observed in the liver microsomes (Figs. 3C and D).

    We also performed a comparison with the metabolic process of BBR in the renal system in vitro. The mouse kidney homogenates and kidney microsomes were treated as described above.After the addition of voriconazole(3.5 μg/mL),BBR could still be metabolized in the kidney homogenate, and M1 and M2 were produced,although also at reduced levels(Figs.3E and F).In addition,similar results were observed in kidney microsomes (Figs. 3G and H).

    This indicated that the addition of voriconazole to the liver and kidney homogenates could inhibit the activity of CYP51, thereby reducing the amount of M1 and M2 produced by BBR metabolism,but the reduction ratio was much lower than that in the gut microbiota.Therefore,it was hypothesized that the key enzyme in the demethylation pathway in the gut was CYP51. In addition, the production of M1 and M2 in kidney homogenate was the lowest(Figs.S1C and D).Compared with the group of kidney homogenate,the production of M1 in liver homogenate was increased by 27%,38%,and 4%at 30,60,and 120 min(Fig.S1C);the production of M2 in liver homogenate increased by 657%, 724%, and 315% at 30, 60,and 120 min, respectively (Fig. S1D). Nevertheless, it could still be seen that the production of M1 and M2 in liver homogenate was much lower than that in gut microbiota (Figs. S1E and F). The production of M1 in gut microbiota was 52.59,69.31,and 84.16 μg/mL at 30, 60, and 120 min (Fig. S1E); the production of M2 in gut microbiota was 132.34,212.45,and 267.40 μg/mL at 30,60,and 120 min,respectively(Fig.S1F).Therefore,it was hypothesized that the gut microbiota was more important to the demethylation of BBR and the key enzyme in the demethylation pathway in the gut was CYP51. In view of the fact that enzymes in the liver and kidneys were likely to participate in the metabolism of BBR in the body,and under the action of voriconazole,BBR still had metabolic processes in the liver and kidneys.Therefore,other metabolic enzymes in the liver and kidneys including drug metabolism P450 enzymes might be involved in the metabolism of BBR. Due to the low absorption rate of BBR, less than 10% of BBR could enter the blood [25].Therefore,although the liver and kidneys had a certain influence on the metabolism of BBR, the demethylation metabolism of BBR in the intestine was more important.

    3.6. Metabolism of BBR in standard bacterial strains in vitro

    Fourteen standard bacterial strains present in the gut microbiota were individually used to investigate the ability of BBR metabolism in vitro, and four standard bacterial strains were selected due to their high production of M1 (Fig. 4A), namely,E. faecalis,S. epidermidis,E. cloacae, andE. faecium.

    These results all directly confirmed the presence of CYP51 in the gut microbiota after each strain was incubated with BBR for 48 h and 72 h. The metabolism of BBR differed among the four strains(Figs. 4B and C). Moreover, the activity of CYP51 differed among different bacterial strains, and the ability of the strains to demethylate BBR was directly proportional to the activity of CYP51(Figs. 4D and E). It was verified that CYP51 was indeed present in the gut microbiota and participated in demethylation-related metabolism.

    However, the level of M1 produced by each strain was significantly reduced (Fig. 4F), while the level of M2 produced by each strain was below the lower limit of quantitation and could not be detected(Fig.4G)after the addition of voriconazole(3.5 μg/mL)for 72 h.In addition,the activity of CYP51 in the four standard bacterial strains incubated with 50 mg/mL BBR for 72 h was not significantly different from that in the strains alone. After the addition of voriconazole (3.5 μg/mL), CYP51 activity was reduced (Fig. 4H).

    This result indicated that voriconazole, a specific inhibitor of CYP51, inhibited most of the activity of CYP51 in bacterial strains,significantly reduced the ability of CYP51 to demethylate BBR for metabolism, and prevented the production of M1 and M2. It was further verified that CYP51 was present in the gut microbiota and is the key enzyme used by the gut microbiota to metabolize BBR to produce a demethylated metabolite.

    3.7. 16S rRNA analysis of the feces of ICR mice after oral administration of BBR

    To explore how BBR affects the gut microbiota, ICR mice were orally administered BBR. Then, the feces of the ICR mice were collected 24 h later and subjected to 16S rRNA sequencing and data analysis, as shown in Fig.5. Compared with the control group, the BBR-treated group exhibited a significant increase in the abundance of one genus(Parabacteroides)(P<0.05,marked in a red“Δ”)and a significant decrease in the abundances of five genera (Tyzzerella 3, Rikenellaceae RC9 gut group, Roseburia, Tyzzerella, Ruminococcus 1) (P<0.05, marked in a blue “Δ”).Parabacteroidesis a potential probiotic genus. Recent studies have found thatParabacteroidesspecies could produce succinate and secondary bile acids to resist body obesity and metabolic dysfunction[26,27];the reduced abundance ofRuminococcus 1validated the role of BBR.Zhang et al. [28] found that the abundance ofRuminococcus 1was significantly increased in rats with high-fat-induced obesity but significantly decreased in rats after BBR administration;Rikenellaceae RC9 gut grouphas also been shown to have important effects on carbohydrates and carbohydrate and lipid metabolism [29].Tyzzerellahas been reported to be greatly enriched in individuals with a high risk of cardiovascular disease [30]. In addition, studies have reported a positive correlation betweenTyzzerella 3and inflammation and hypertension [31,32]. Furthermore, the abundance of one taxon (Porphyromonadaceae) exhibited a significant increase (Fig. S2) at the family level (P< 0.05), which also confirmed the regulatory effect of BBR on the gut microbiota [33].The above results proved that BBR changed the gut microbiota after oral administration and altered its own metabolism by the gut microbiota. To investigate whether voriconazole affected the gut microbiota, ICR mice were orally administered BBR and voriconazole. The abundances ofParabacteroides,Tyzzerella 3,Rikenellaceae RC9 gut group,Roseburia,Tyzzerella, Ruminococcus 1and Porphyromonadaceae, which were originally changed, did not change significantly after the addition of voriconazole (Fig. S3).

    Fig.6.Effect of the CYP51 enzyme lysate on demethylation of BBR.(A)CYP51 plasmid sequence.(B)CYP51 was present in the enzyme lysate(1:marker;2:the protein contained in the precipitate of E. coli BL21 without pet28a-cyp51 before induction; 3: the protein contained in the supernatant of E. coli BL21 without pet28a-cyp51 before induction; 4: the protein contained in the precipitate of E. coli BL21 without pet28a-cyp51 after induction; 5: the protein contained in the supernatant of E. coli BL21 without pet28a-cyp51 after induction; 6: the protein contained in the precipitate of E. coli BL21 with pet28a-cyp51 before induction; 7: the protein contained in the supernatant of E. coli BL21 with pet28acyp51 before induction;8:the protein contained in the precipitate of E.coli BL21 with pet28a-cyp51 after induction;9:the protein contained in the supernatant of E.coli BL21 with pet28a-cyp51 after induction).(C)Relative proportions of lanosterol after incubation for 0,1,2,and 4 h in the enzymatic reaction system of the CYP51 enzyme lysate compared with the control enzyme lysate.*P <0.05.(D)Relative peak area of 14-demethyl-14-dehydrolanosterol(FF-MAS)after 0,1,2,and 4 h of incubation in the enzymatic reaction system of the CYP51 enzyme lysate. * P <0.05; ** P <0.01; ND: not detected. (E and F) Relative proportions of M1 and M2 after 0,1, 2, and 4 h of incubation in the CYP51 enzyme lysate compared with the control enzyme lysate. * P <0.05; ** P <0.01.

    3.8. Metabolism of BBR in CYP51 enzyme lysate

    Recombinant plasmid containing theCYP51gene was constructed(Figs.6A and S4A),and transformed intoE.coliBL21(DE3)cells.The CYP51 protein was expressed inE.colias accessed by SDSPAGE analysis (Fig. 6B). Lanosterol, the classic substrate of CYP51,was selected to verify the function of the CYP51 enzyme lysate.As shown in Fig.6C,the lanosterol level decreased significantly under the action of CYP51 enzyme lysate compared with the control.The production ratio of its demethylated metabolite,FF-MAS,increased significantly(Fig.6D),while the FF-MAS level was below the lower limit of quantitation after the reaction of lanosterol with the control enzyme lysate (Fig. S4B). BBR was added to the CYP51 enzyme lysate system, and the production ratios of M1 and M2 were significantly increased compared with that of the control (Figs. 6E and F), which verified that CYP51 was the key enzyme of the gut microbiota that promoted the metabolism of BBR to produce demethylated metabolites.

    4. Conclusion

    BBR is a safe drug with multiple therapeutic effects in the clinic.Due to the low absorption rate of BBR in the gut microbiota, the activity of its metabolites is particularly important.In this research,it was first suggested that CYP51 was present in the gut microbiota,and BBR was metabolized by CYP51 in the intestine to produce demethylated metabolites M1 and M2, which provided a basis for the study of metabolic conversion mechanisms of various isoquinoline alkaloids in vivo and expanded our understanding of the role of the gut microbiota in drug metabolism with demethylation reaction.

    Declaration of competing interest

    The authors declare that there are no conflicts of interest.

    Acknowledgments

    The project was supported by CAMS Innovation Fund for Medical Sciences (CIFMS, Grant No.: 2016-I2M-3-011, China), the National Natural Science Foundation of China (Grant Nos.: 81803613 and 81973290), Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study (Grant No.: Z141102004414062,China), Beijing Natural Sciences Fund Key Projects (Grant No.:7181007)and the National Megaproject for Innovative Drugs(Grant No.:2018ZX09711001-002-002).We would like to thank Shimadzu(China) Co., Ltd. for technological support.

    Appendix A. Supplementary data

    Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpha.2020.10.001.

    六月丁香七月| 99热这里只有精品一区| 亚洲伊人久久精品综合 | 51国产日韩欧美| 少妇的逼好多水| 国产女主播在线喷水免费视频网站 | av专区在线播放| 免费看av在线观看网站| 亚洲五月天丁香| 亚洲美女视频黄频| 欧美一级a爱片免费观看看| 国产精品女同一区二区软件| 国产免费一级a男人的天堂| kizo精华| 中文乱码字字幕精品一区二区三区 | 男人的好看免费观看在线视频| 免费看美女性在线毛片视频| www.色视频.com| 国产极品天堂在线| 天天一区二区日本电影三级| 日本一本二区三区精品| 一级av片app| 男人的好看免费观看在线视频| 听说在线观看完整版免费高清| 久久久午夜欧美精品| 精品国产三级普通话版| 三级男女做爰猛烈吃奶摸视频| a级一级毛片免费在线观看| 欧美成人精品欧美一级黄| 中文乱码字字幕精品一区二区三区 | 亚洲精品一区蜜桃| 激情 狠狠 欧美| 亚洲精品色激情综合| 97人妻精品一区二区三区麻豆| 日本黄大片高清| 少妇熟女aⅴ在线视频| 高清在线视频一区二区三区 | 热99re8久久精品国产| 一区二区三区四区激情视频| 九色成人免费人妻av| 91aial.com中文字幕在线观看| 久久久亚洲精品成人影院| 伦精品一区二区三区| 久久久a久久爽久久v久久| 嘟嘟电影网在线观看| 国产在视频线精品| 观看美女的网站| 国产一区二区亚洲精品在线观看| 少妇被粗大猛烈的视频| 国产爱豆传媒在线观看| 白带黄色成豆腐渣| 午夜视频国产福利| 丝袜喷水一区| 久久久久网色| 在现免费观看毛片| videossex国产| 18禁在线播放成人免费| 亚洲美女视频黄频| 只有这里有精品99| 亚洲欧美成人精品一区二区| 亚洲av电影不卡..在线观看| 亚洲欧美中文字幕日韩二区| 色播亚洲综合网| 日韩强制内射视频| av.在线天堂| 亚洲成av人片在线播放无| 18禁动态无遮挡网站| 九九爱精品视频在线观看| 老司机影院成人| av视频在线观看入口| 色哟哟·www| 我的女老师完整版在线观看| 精品人妻视频免费看| 成人毛片60女人毛片免费| 亚洲欧美日韩东京热| 又黄又爽又刺激的免费视频.| 成年免费大片在线观看| 日本欧美国产在线视频| 亚洲欧美日韩卡通动漫| 国产精品精品国产色婷婷| 日韩欧美三级三区| 亚洲av成人精品一二三区| 欧美日本亚洲视频在线播放| 色网站视频免费| 白带黄色成豆腐渣| 国产成人精品久久久久久| 欧美+日韩+精品| 亚洲av成人精品一区久久| 精品久久久久久成人av| 国产真实乱freesex| 超碰av人人做人人爽久久| 亚洲国产高清在线一区二区三| 身体一侧抽搐| 国产白丝娇喘喷水9色精品| 亚洲国产日韩欧美精品在线观看| 国产免费又黄又爽又色| 免费看日本二区| 久久精品国产99精品国产亚洲性色| 午夜激情欧美在线| 少妇裸体淫交视频免费看高清| 久久婷婷人人爽人人干人人爱| 亚洲自拍偷在线| 边亲边吃奶的免费视频| 精品国产一区二区三区久久久樱花 | 亚洲国产最新在线播放| 国产一区二区在线av高清观看| 97超视频在线观看视频| 国产极品天堂在线| 久久久欧美国产精品| 直男gayav资源| 女人被狂操c到高潮| 久久精品国产亚洲网站| 欧美xxxx性猛交bbbb| 国产亚洲精品久久久com| 国产精品久久视频播放| 亚洲aⅴ乱码一区二区在线播放| 最近视频中文字幕2019在线8| 国产一区二区亚洲精品在线观看| 国产成人精品婷婷| 五月玫瑰六月丁香| 美女国产视频在线观看| 草草在线视频免费看| 18禁动态无遮挡网站| 亚洲国产欧美人成| 国产精品人妻久久久影院| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 欧美3d第一页| 少妇人妻精品综合一区二区| 春色校园在线视频观看| 一边摸一边抽搐一进一小说| 一区二区三区免费毛片| 综合色丁香网| 狠狠狠狠99中文字幕| 乱人视频在线观看| 精品久久久久久久久av| 亚洲乱码一区二区免费版| 国产乱人视频| 亚洲精品aⅴ在线观看| 久久久久久九九精品二区国产| 大话2 男鬼变身卡| 国产高潮美女av| 久久久久久久久久久免费av| 人妻制服诱惑在线中文字幕| 看十八女毛片水多多多| 人人妻人人澡人人爽人人夜夜 | 成人高潮视频无遮挡免费网站| 成人一区二区视频在线观看| 一级爰片在线观看| 中文在线观看免费www的网站| 久久久欧美国产精品| 国产又色又爽无遮挡免| 可以在线观看毛片的网站| 午夜精品一区二区三区免费看| 蜜桃久久精品国产亚洲av| 三级国产精品片| 精品无人区乱码1区二区| 亚洲精品乱码久久久v下载方式| 国产精品久久久久久久久免| 国产v大片淫在线免费观看| 一本一本综合久久| 最后的刺客免费高清国语| 男人的好看免费观看在线视频| 一本一本综合久久| 一本一本综合久久| 99久国产av精品国产电影| 一级毛片我不卡| 好男人在线观看高清免费视频| 最近的中文字幕免费完整| 欧美xxxx性猛交bbbb| 99热这里只有是精品在线观看| 成人二区视频| 中文字幕制服av| 欧美成人午夜免费资源| 国产真实乱freesex| 精品免费久久久久久久清纯| 精品免费久久久久久久清纯| 亚洲av熟女| 毛片一级片免费看久久久久| 能在线免费看毛片的网站| 国内精品宾馆在线| 国产亚洲精品久久久com| 精品一区二区三区视频在线| 水蜜桃什么品种好| 精品无人区乱码1区二区| 色视频www国产| 麻豆av噜噜一区二区三区| 99热这里只有是精品在线观看| 成年免费大片在线观看| 如何舔出高潮| 久久人妻av系列| 天堂av国产一区二区熟女人妻| 精品久久久久久久人妻蜜臀av| 欧美成人午夜免费资源| 成人性生交大片免费视频hd| 2021少妇久久久久久久久久久| 亚洲四区av| 中文乱码字字幕精品一区二区三区 | 超碰97精品在线观看| 亚洲不卡免费看| 91精品一卡2卡3卡4卡| 热99在线观看视频| 2021少妇久久久久久久久久久| 中文在线观看免费www的网站| 成人亚洲欧美一区二区av| 亚洲av.av天堂| 爱豆传媒免费全集在线观看| 久久久久网色| 别揉我奶头 嗯啊视频| 纵有疾风起免费观看全集完整版 | 日韩av不卡免费在线播放| 亚洲国产欧洲综合997久久,| 亚洲欧美日韩高清专用| 九九爱精品视频在线观看| 永久免费av网站大全| 亚洲自拍偷在线| av在线天堂中文字幕| 亚洲一区高清亚洲精品| 青春草视频在线免费观看| 久久久久久九九精品二区国产| 欧美精品国产亚洲| 少妇猛男粗大的猛烈进出视频 | 一级毛片我不卡| 精品久久久久久久久久久久久| 波野结衣二区三区在线| 国产精品日韩av在线免费观看| 99热这里只有是精品在线观看| 欧美日韩国产亚洲二区| 亚洲国产精品专区欧美| 成人性生交大片免费视频hd| 欧美+日韩+精品| 亚洲精品色激情综合| 国产淫片久久久久久久久| 天堂av国产一区二区熟女人妻| 午夜a级毛片| 亚洲国产最新在线播放| 国产成人a区在线观看| 亚洲中文字幕日韩| 一个人免费在线观看电影| 久久久久久久国产电影| 你懂的网址亚洲精品在线观看 | 久久精品国产鲁丝片午夜精品| 一区二区三区高清视频在线| 99九九线精品视频在线观看视频| 亚洲欧美中文字幕日韩二区| 亚洲欧美日韩东京热| 亚洲美女视频黄频| 婷婷色av中文字幕| 夫妻性生交免费视频一级片| 国产极品天堂在线| 99久国产av精品国产电影| 精品久久久久久久人妻蜜臀av| 日本五十路高清| 午夜老司机福利剧场| 天堂影院成人在线观看| 国产精品一区二区性色av| 校园人妻丝袜中文字幕| 中文字幕人妻熟人妻熟丝袜美| 三级经典国产精品| 爱豆传媒免费全集在线观看| 日韩 亚洲 欧美在线| 国产成人一区二区在线| 亚洲18禁久久av| 午夜激情欧美在线| 麻豆久久精品国产亚洲av| 亚洲欧洲日产国产| 午夜精品国产一区二区电影 | 在线播放无遮挡| 99久久中文字幕三级久久日本| 日本黄色片子视频| a级一级毛片免费在线观看| 国产伦精品一区二区三区视频9| 亚洲人与动物交配视频| 熟妇人妻久久中文字幕3abv| 久久精品综合一区二区三区| 又爽又黄无遮挡网站| 国产免费福利视频在线观看| 国产精品三级大全| 卡戴珊不雅视频在线播放| 国产亚洲av片在线观看秒播厂 | 亚洲,欧美,日韩| 成年女人看的毛片在线观看| 嫩草影院新地址| 国产乱来视频区| 国产在线男女| 亚洲乱码一区二区免费版| 一本一本综合久久| 特级一级黄色大片| 国产精品精品国产色婷婷| 午夜福利成人在线免费观看| 全区人妻精品视频| 成人午夜高清在线视频| av线在线观看网站| av国产免费在线观看| 亚洲精品影视一区二区三区av| 天堂影院成人在线观看| 少妇被粗大猛烈的视频| 亚洲精品国产av成人精品| 99久久人妻综合| 自拍偷自拍亚洲精品老妇| 日日摸夜夜添夜夜爱| 亚洲天堂国产精品一区在线| 国产乱人视频| 最近中文字幕高清免费大全6| 精品人妻一区二区三区麻豆| 婷婷六月久久综合丁香| 非洲黑人性xxxx精品又粗又长| 人妻夜夜爽99麻豆av| a级毛片免费高清观看在线播放| 精品人妻一区二区三区麻豆| 国产亚洲5aaaaa淫片| 亚洲国产精品成人久久小说| 看免费成人av毛片| 亚洲精品自拍成人| 91在线精品国自产拍蜜月| 午夜久久久久精精品| 国产 一区精品| 国产免费视频播放在线视频 | 尤物成人国产欧美一区二区三区| 久99久视频精品免费| 欧美+日韩+精品| 亚洲欧洲日产国产| 在线播放国产精品三级| 九九久久精品国产亚洲av麻豆| 国产美女午夜福利| 精品酒店卫生间| 我要搜黄色片| 国产成人a区在线观看| 日韩制服骚丝袜av| 久久精品夜色国产| 国产精品1区2区在线观看.| 国产av不卡久久| 99九九线精品视频在线观看视频| 成人一区二区视频在线观看| 日本wwww免费看| 国产精品伦人一区二区| 精品不卡国产一区二区三区| 日日干狠狠操夜夜爽| 国产久久久一区二区三区| 亚洲乱码一区二区免费版| 一区二区三区乱码不卡18| 一级av片app| 成人毛片60女人毛片免费| 麻豆国产97在线/欧美| 乱码一卡2卡4卡精品| 欧美又色又爽又黄视频| 午夜激情福利司机影院| 国产精品.久久久| 久久婷婷人人爽人人干人人爱| 亚洲欧美精品综合久久99| 国内精品美女久久久久久| 亚洲综合精品二区| 国产精品乱码一区二三区的特点| 色综合站精品国产| 韩国av在线不卡| 日韩国内少妇激情av| 国内精品一区二区在线观看| 丰满乱子伦码专区| 国产又黄又爽又无遮挡在线| 亚洲一级一片aⅴ在线观看| 啦啦啦啦在线视频资源| 又粗又爽又猛毛片免费看| 国产免费视频播放在线视频 | 欧美最新免费一区二区三区| 99九九线精品视频在线观看视频| 亚洲性久久影院| 久久久久久伊人网av| 欧美色视频一区免费| www.av在线官网国产| АⅤ资源中文在线天堂| 欧美97在线视频| 色噜噜av男人的天堂激情| 啦啦啦啦在线视频资源| 91久久精品电影网| 1024手机看黄色片| 大香蕉久久网| 亚洲av成人av| 免费观看精品视频网站| 精品人妻视频免费看| 美女高潮的动态| 欧美三级亚洲精品| 2021少妇久久久久久久久久久| 天天一区二区日本电影三级| 一夜夜www| 欧美潮喷喷水| 久久久久久大精品| 真实男女啪啪啪动态图| 国产真实伦视频高清在线观看| 秋霞在线观看毛片| 成人毛片60女人毛片免费| 国产老妇伦熟女老妇高清| 国产精品乱码一区二三区的特点| 又粗又硬又长又爽又黄的视频| 丝袜喷水一区| 亚洲av成人精品一二三区| 亚洲精品乱码久久久v下载方式| 1000部很黄的大片| 国产高清有码在线观看视频| 天堂网av新在线| 午夜日本视频在线| 国产黄色视频一区二区在线观看 | 能在线免费看毛片的网站| 欧美日本视频| 我的女老师完整版在线观看| 亚洲人成网站高清观看| 国产不卡一卡二| 老司机福利观看| 波多野结衣高清无吗| 久久久久性生活片| 成人毛片a级毛片在线播放| 在线观看美女被高潮喷水网站| 中国美白少妇内射xxxbb| 亚洲av免费在线观看| 亚洲av成人精品一区久久| 久久精品国产自在天天线| 国产精品久久电影中文字幕| 2021天堂中文幕一二区在线观| 女人十人毛片免费观看3o分钟| 91精品一卡2卡3卡4卡| 亚洲国产精品专区欧美| 日本一本二区三区精品| 26uuu在线亚洲综合色| 欧美3d第一页| 久久精品人妻少妇| 亚洲av免费高清在线观看| 国产精品国产高清国产av| 男女视频在线观看网站免费| 国产伦在线观看视频一区| 日韩成人av中文字幕在线观看| 国产又色又爽无遮挡免| av免费在线看不卡| 99热精品在线国产| 黄片wwwwww| 亚洲不卡免费看| 国产 一区精品| av卡一久久| 高清视频免费观看一区二区 | 国产女主播在线喷水免费视频网站 | 国产伦精品一区二区三区视频9| 国产精品久久久久久精品电影小说 | 亚洲国产日韩欧美精品在线观看| 亚洲av成人av| 波多野结衣巨乳人妻| 99久久中文字幕三级久久日本| 欧美激情在线99| 欧美高清成人免费视频www| 爱豆传媒免费全集在线观看| 中文字幕久久专区| av免费在线看不卡| 如何舔出高潮| 亚洲av.av天堂| 国产精品久久电影中文字幕| 久久久久久久久久黄片| 国产在视频线在精品| 久久99热这里只有精品18| 成人二区视频| 91久久精品电影网| 乱系列少妇在线播放| 午夜免费男女啪啪视频观看| 久久99热这里只频精品6学生 | 精品久久久久久成人av| 久久热精品热| 久久精品国产99精品国产亚洲性色| 黄片wwwwww| 老女人水多毛片| 久久久久久国产a免费观看| 国产成人a区在线观看| 国产一区二区在线观看日韩| 成人亚洲精品av一区二区| 男的添女的下面高潮视频| 国产69精品久久久久777片| 天天躁夜夜躁狠狠久久av| 啦啦啦啦在线视频资源| 久久久久久九九精品二区国产| 亚洲最大成人手机在线| 蜜臀久久99精品久久宅男| 国产真实乱freesex| 日本与韩国留学比较| 99热6这里只有精品| 人体艺术视频欧美日本| 国模一区二区三区四区视频| 色5月婷婷丁香| 亚洲国产精品成人综合色| 天天一区二区日本电影三级| 久久国内精品自在自线图片| 亚洲电影在线观看av| 精品无人区乱码1区二区| 国内少妇人妻偷人精品xxx网站| 一级av片app| 国产午夜精品久久久久久一区二区三区| 欧美激情在线99| 国产极品精品免费视频能看的| 久久午夜福利片| 麻豆久久精品国产亚洲av| 国产亚洲精品久久久com| 国产三级中文精品| 人妻系列 视频| 亚洲精品aⅴ在线观看| 一级av片app| 国产一区二区三区av在线| 99久久人妻综合| 亚洲美女视频黄频| 级片在线观看| 精品人妻视频免费看| 国产大屁股一区二区在线视频| 亚洲av成人精品一二三区| 成人一区二区视频在线观看| 狠狠狠狠99中文字幕| 国产午夜福利久久久久久| 99热这里只有是精品在线观看| 国内揄拍国产精品人妻在线| 美女被艹到高潮喷水动态| 狠狠狠狠99中文字幕| 亚洲欧美精品自产自拍| 久久精品国产99精品国产亚洲性色| 国产精品,欧美在线| 亚洲欧美成人精品一区二区| 一边摸一边抽搐一进一小说| 神马国产精品三级电影在线观看| 亚洲美女搞黄在线观看| 九色成人免费人妻av| 久久鲁丝午夜福利片| 国产精品熟女久久久久浪| 亚洲欧美日韩无卡精品| 国产成人a区在线观看| 综合色丁香网| 日本黄大片高清| 国产一级毛片在线| 爱豆传媒免费全集在线观看| 久久久久久久久久成人| 亚洲欧美清纯卡通| 91aial.com中文字幕在线观看| 久久久a久久爽久久v久久| 18禁在线播放成人免费| 国产老妇女一区| 三级毛片av免费| 美女大奶头视频| 女的被弄到高潮叫床怎么办| 亚洲av中文av极速乱| 免费在线观看成人毛片| 男的添女的下面高潮视频| 精品99又大又爽又粗少妇毛片| 搡女人真爽免费视频火全软件| 午夜视频国产福利| 中国国产av一级| 国产熟女欧美一区二区| 插阴视频在线观看视频| 神马国产精品三级电影在线观看| 狠狠狠狠99中文字幕| 国产成人精品久久久久久| 欧美成人一区二区免费高清观看| 国产精品国产三级专区第一集| 久久精品国产亚洲网站| 美女黄网站色视频| 成人综合一区亚洲| 一二三四中文在线观看免费高清| 99久久九九国产精品国产免费| 亚洲成人久久爱视频| 日韩av不卡免费在线播放| 国产在线一区二区三区精 | 久久综合国产亚洲精品| av.在线天堂| 国产亚洲精品久久久com| 美女大奶头视频| 亚洲人成网站在线播| 精品久久久久久久久av| 波多野结衣巨乳人妻| 丰满少妇做爰视频| 国产免费福利视频在线观看| 亚洲国产成人一精品久久久| 日韩制服骚丝袜av| 欧美一级a爱片免费观看看| 欧美一区二区国产精品久久精品| 白带黄色成豆腐渣| 禁无遮挡网站| 美女大奶头视频| 久久精品国产鲁丝片午夜精品| 狂野欧美激情性xxxx在线观看| 不卡视频在线观看欧美| 能在线免费观看的黄片| 免费看a级黄色片| 久久久精品大字幕| 变态另类丝袜制服| 白带黄色成豆腐渣| 午夜免费激情av| 国产一区二区三区av在线| 99热这里只有精品一区| 国产亚洲午夜精品一区二区久久 | 免费看a级黄色片| 极品教师在线视频| 免费观看a级毛片全部| 久久精品熟女亚洲av麻豆精品 | 岛国在线免费视频观看| 久久久久久久国产电影| 国国产精品蜜臀av免费| 午夜视频国产福利| 有码 亚洲区| 18禁动态无遮挡网站| 成人高潮视频无遮挡免费网站| 乱系列少妇在线播放| 欧美日本亚洲视频在线播放| 亚洲在线自拍视频| 亚洲欧洲国产日韩| 国产午夜精品论理片| 91久久精品国产一区二区成人| 国产乱人视频| 亚洲综合精品二区| 亚洲国产精品sss在线观看| 国产91av在线免费观看| 亚洲国产欧美在线一区| 尾随美女入室| 1024手机看黄色片| 人妻制服诱惑在线中文字幕| 少妇熟女欧美另类| 成人三级黄色视频| 久久这里有精品视频免费|